In recent years, genetic polymorphisms of NAT2, CYP2E1 as well as GSTs have gained more focus by linking patient’s genetic susceptibility to anti-TB drug-induced hepatitis. This evidence concerns the gene NAT2 and hepatitis A virus infection.